Annals of Oncology
Is Adjuvant Ribociclib Ready for Prime Time?
Natarajan A, Tolaney SM
In 2021, data from the monarchE trial led to U.S. Food and Drug Administration approval of adjuvant abemaciclib in combination with endocrine therapy (ET) for patients with high-risk hormone receptor-positive (HR+) early breast cancer (EBC).?Recent data from the NATALEE trial has led to a broad FDA approval for adjuvant ribociclib in combination with an aromatase inhibitor for stage II and III HR+ EBC, including those with high-risk node-negative disease. This data leaves us with the question: how do we incorporate ribociclib in routine clinical practice?
|
Blood
Baseline Immune State and T-Cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-Cell Lymphoma
Maurer K, Grabski IN, Houot R, Gohil SH, Miura S, Redd R, Lyu H, Lu W, Arihara Y, McDonough M, Ansuinelli M, Reynolds C, Jacene H, Li S, Livak KJ, Ritz J, Neuberg DS, Irizarry RA, Armand P, Wu CJ, Jacobson C
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T cells (CAR-Ts) has revolutionized outcomes for patients with relapsed/refractory large B-cell lymphoma (LBCL), but the cellular and molecular features associated with response remain largely unresolved. We analyzed serial peripheral blood samples ranging from the day of apheresis (day -28/baseline) to 28 days after CAR-T infusion from 50 patients with LBCL treated with axicabtagene ciloleucel by integrating single-cell RNA and T-cell receptor sequencing, flow cytometry, and mass cytometry to characterize features associated with response to CAR-T. Pretreatment patient characteristics associated with response included the presence of B cells and increased absolute lymphocyte count to absolute monocyte count ratio (ALC/AMC). Infusion products from responders were enriched for clonally expanded, highly activated CD8+ T cells. We expanded these observations to 99 patients from the ZUMA-1 cohort and identified a subset of patients with elevated baseline B cells, 80% of whom were complete responders. We integrated B-cell proportion ?0.5% and ALC/AMC ?1.2 into a 2-factor predictive model and applied this model to the ZUMA-1 cohort. Estimated progression-free survival at 1 year in patients meeting 1 or both criteria was 65% vs 31% for patients meeting neither criterion. Our results suggest that patients' immunologic state at baseline affects the likelihood of response to CAR-T through both modulation of the T-cell apheresis product composition and promoting a more favorable circulating immune compartment before therapy. These baseline immunologic features, measured readily in the clinical setting before CAR-T, can be applied to predict response to therapy.
|
Blood
Moving Forward in Good KarMMa in Myeloma
Bianchi G
In this issue of?Blood,?Ailawadhi and colleagues?report on the preplanned final analysis of progression-free survival (PFS) at a median follow-up of 30.9 months in patients with triple-class–exposed multiple myeloma (MM) enrolled in the KarMMa-3 study.?With nearly 3 years of follow-up, this study is relevant in outlining no new, unexpected, and/or increased toxicities as compared with the initial report, and in confirming the efficacy of idecabtagene vicleucel (ide-cel) compared with standard regimens (SRs) in patients with relapsed and refractory MM (RRMM).
|
Cancer Cell
Cytokines in Cancer
Kureshi CT, Dougan SK
Cytokines are proteins used by immune cells to communicate with each other and with cells in their environment. The pleiotropic effects of cytokine networks are determined by which cells express cytokines and which cells express cytokine receptors, with downstream outcomes that can differ based on cell type and environmental cues. Certain cytokines, such as interferon (IFN)-?, have been clearly linked to anti-tumor immunity, while others, such as the innate inflammatory cytokines, promote oncogenesis. Here we provide an overview of the functional roles of cytokines in the tumor microenvironment. Although we have a sophisticated understanding of cytokine networks, therapeutically targeting cytokine pathways in cancer has been challenging. We discuss current progress in cytokine blockade, cytokine-based therapies, and engineered cytokine therapeutics as emerging cancer treatments of interest.
|
Cell Stem Cell
Gene Editing without Ex?Vivo Culture Evades Genotoxicity in Human Hematopoietic Stem Cells
Zeng J, Nguyen MA, da Silva LF, Levesque S, Lin LY, Justus DG, Petri K, Clement K, Verma A, Neri NR, Rosanwo T, Ciuculescu MF, Abriss D, Cha HJ, Orkin SH, Williams DA, Pinello L, Joung JK, Pattanayak V, Manis JP, Armant M, Pellin D, Brendel C, Wolfe SA, Bauer DE
Gene editing the BCL11A erythroid enhancer is a validated approach to fetal hemoglobin (HbF) induction for ?-hemoglobinopathy therapy, though heterogeneity in edit allele distribution and HbF response may impact its safety and efficacy. Here, we compare combined CRISPR-Cas9 editing of the BCL11A?+58 and?+55 enhancers with leading gene modification approaches under clinical investigation. Dual targeting of the BCL11A?+58 and?+55 enhancers with 3xNLS-SpCas9 and two single guide RNAs (sgRNAs) resulted in superior HbF induction, including in sickle cell disease (SCD) patient xenografts, attributable to simultaneous disruption of core half E-box/GATA motifs at both enhancers. Unintended on-target outcomes of double-strand break (DSB) repair in hematopoietic stem and progenitor cells (HSPCs), such as long deletions and centromere-distal chromosome fragment loss, are a byproduct of cellular proliferation stimulated by ex?vivo culture. Editing quiescent HSPCs bypasses long deletion and micronuclei formation and preserves efficient on-target editing and engraftment function.
|
JAMA
Active Monitoring with or without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial
Schnitt S, Partridge AH
IMPORTANCE: Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown.
OBJECTIVE: To compare rates of invasive cancer in patients with low-risk DCIS receiving active monitoring vs guideline-concordant care.
DESIGN, SETTING, AND PARTICIPANTS: Prospective, randomized noninferiority trial enrolling 995 women aged 40 years or older with a new diagnosis of hormone receptor-positive grade 1 or grade 2 DCIS without invasive cancer at 100 US Alliance Cancer Cooperative Group clinical trial sites from 2017 to 2023.
INTERVENTIONS: Participants were randomized to receive active monitoring (follow-up every 6 months with breast imaging and physical examination; n?=?484) or guideline-concordant care (surgery with or without radiation therapy; n?=?473).
MAIN OUTCOMES AND MEASURES: The primary outcome was 2-year cumulative risk of ipsilateral invasive cancer diagnosis, according to planned intention-to-treat and per-protocol analyses, with a noninferiority bound of 0.05%.
RESULTS: The median age of the 957 participants analyzed was 63.6 (95% CI, 55.5-70.5) years in the guideline-concordant care group and 63.7 (95% CI, 60.0-71.6) years in the active monitoring group. Overall, 15.7% of participants were Black and 75.0% were White. In this prespecified primary analysis, median follow-up was 36.9 months; 346 patients had surgery for DCIS, 264 in the guideline-concordant care group and 82 in the active monitoring group. Forty-six women were diagnosed with invasive cancer, 19 in the active monitoring group and 27 in the guideline-concordant care group. The 2-year Kaplan-Meier cumulative rate of ipsilateral invasive cancer was 4.2% in the active monitoring group vs 5.9% in the guideline-concordant care group, a difference of -1.7% (upper limit of the 95% CI, 0.95%), indicating that active monitoring is not inferior to guideline-concordant care. Invasive tumor characteristics did not differ significantly between groups.
CONCLUSIONS AND RELEVANCE: Women with low-risk DCIS randomized to active monitoring did not have a higher rate of invasive cancer in the same breast at 2 years compared with those randomized to guideline-concordant care.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02926911.
|
JAMA
Allogeneic Stem Cell Donation
Amonoo HL
Hematopoietic stem cell transplant (HSCT) is a potentially life-saving therapy for hematologic and bone marrow cancers (eg, leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes) and nonmalignant conditions (eg, sickle cell disease, aplastic anemia) in adults and children. Autologous stem cell transplant (auto-HSCT) involves the transplant of a patient’s own stem cells, while allogeneic stem cell transplant (allo-HSCT) involves the transplant of a related or unrelated donor’s stem cells (eTable in the?Supplement). The Center for International Blood and Marrow Transplant Research reported that approximately 20?000 HSCTs were performed in the US in 2023, of which 11?139 were auto-HSCT and 8218 were allo-HSCT.
|
JAMA
The Promise and Perils of Diversity Action Plans for Clinical Trials
Varma T, Bierer BE, Hantel A
Enacted on December 29, 2022, the Food and Drug Omnibus Reform Act of 2022 (FDORA)?included novel provisions for advancing clinical trial diversity. Specifically, FDORA granted the US Food and Drug Administration (FDA) the statutory authority to require drug and device sponsors to submit diversity action plans (DAPs) that must specify enrollment goals by race, ethnicity, sex, and age. Although Congress had previously enacted legislation encouraging clinical trial diversity, this was the first time it required clinical trial sponsors to develop plans for advancing demographic representation. Following the FDORA mandate, the FDA revised and published draft guidance on the format and content of DAPs on June 26, 2024.
|
JAMA Oncology
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial
Partridge AH
IMPORTANCE: Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM for DCIS are lacking.
OBJECTIVE: To compare PROs at baseline and over time in patients with low-risk DCIS randomized to receive either AM or GCC.
DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary outcome analysis used prospectively collected validated questionnaires at baseline, 6 months, 1 year, and 2 years from participants enrolled from June 2017 to January 2023 in the Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) study for low-risk DCIS, which randomized participants to receive GCC or AM.
INTERVENTION: Randomization to GCC or AM.
MAIN OUTCOMES AND MEASURES: Context-relevant PROs, including health-related quality of life, anxiety, depression, and symptoms measured by validated survey instruments. Mixed models, including sensitivity analyses, with group, point, and group-by-point effects were used to compare PROs between groups.
RESULTS: Of the 957 participants in COMET, 225 (24%) were younger than 55 years at enrollment, 325 (34%) were aged 55 to 65 years, and 403 (42%) were older than 65 years, and 953 (99.5%) completed questionnaires at some point within the first 2 years, with a completion rate of more than 83% at all points. Quality of life, anxiety, depression, worries about DCIS, and symptom trajectories were comparable between groups, with modest fluctuations over time of limited clinical significance. Physical functioning was the only specific Medical Outcomes Study 36-item short-form health survey (SF-36) domain for which changes in the score trajectory differed by group over time, with mean scores ranging from 50 (baseline) to 48 (6, 12, and 24 months) in the GCC group and 50 (baseline) to 47 (12 months) and 48 (6 and 24 months) in the AM group (pooled SD, 9.9; P?=?.01), although these were also of limited clinical significance.
CONCLUSIONS AND RELEVANCE: In this prespecified secondary analysis of the COMET prospective randomized trial, the overall lived experience of women randomized to undergo AM for low-risk DCIS was similar to that of women randomized to GCC during the 2 years following diagnosis.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02926911.
|
Journal of Clinical Oncology
A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease
Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Arnason JE, Ahn IE, Brown JR
PURPOSE: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard of care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wildtype TP53; however, due to the chemoimmunotherapy control arm, AMPLIFY excluded patients with the high-risk TP53 aberration, for whom current standards of care are continuous Bruton tyrosine kinase inhibitor therapy or alternatively fixed-duration venetoclax-based doublets. AVO has not previously been evaluated in patients with CLL with TP53 aberration.
PATIENTS AND METHODS: This investigator-sponsored, multicenter, phase 2 study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by TP53 aberration (NCT03580928). Patients received acalabrutinib, obinutuzumab, and then venetoclax, with each treatment introduced sequentially and in combination, with the duration guided by measurable residual disease (MRD). Patients who achieved undetectable MRD (uMRD) after either fifteen or twenty-four cycles could discontinue treatment. The primary endpoint was complete response (CR) with bone marrow uMRD (BM-uMRD) at the start of cycle 16.
RESULTS: Seventy-two patients were accrued, including 45 patients with TP53 aberration. The CR with BM-uMRD rates at the start of cycle 16 were 42% in patients with TP53 aberration and 42% in all-comers, and the BM-uMRD rates were 71% and 78%, respectively. Hematologic toxicities were mainly low-grade, and cardiovascular toxicities and bleeding complications were infrequent. After a median follow-up of 55.2 months, ten patients had progressed, including 4 with transformation, and three patients died. Four-year progression-free and overall survival for patients with or without TP53 aberration were 70%/96% and 88%/100%, respectively.
CONCLUSIONS: AVO was highly active and well-tolerated in patients with previously untreated CLL with high-risk CLL, supporting its use as a new standard of care treatment option.
|
Journal of Clinical Oncology
Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality
Venkataraman V, Salmi L, Claus EB, Diehl D, Janeway KA, Mack JW, George S
Direct participant engagement in research, defined as involving ongoing, bidirectional, and mutually beneficial interactions among participants and researchers where participants are included as an integral part throughout the research process, is critical for cancer research and a central tenet of the Cancer Moonshot. As described by the National Cancer Institute (NCI), engaging patients and the public in cancer research is critical to understanding the biology of cancer, how to prevent and treat it, and how to deliver care to all people with cancer.
|
Journal of the National Cancer Institute
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
Sharon E
Background: Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluated, with most prior research finding a positive association between toxicity and survival. This prior research has generally reported on more common tumor types. We use a unique data resource of a federally-funded basket trial ((NCT02834013) for patients with rare cancers (N = 684) to evaluate associations between irAEs and overall survival and progression-free survival.
Methods: Patients were treated with nivolumab and ipilimumab; the trial was opened at > 1000 sites. Landmark Cox regression models were used to assess first cycle irAE associations with progression-free and overall survival.
Results: We found that grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival (OS) (multivariable hazard ratio, 95% confidence interval, p-value: 0.61, 0.49-0.75, p < .001) compared to no treatment-related irAE, while grade 3-4 irAEs were associated with shorter OS (HR = 1.41, 95% CI = 1.04-1.90, p = .025). Similar, but weaker, associations were observed with progression-free survival (PFS) and grade 1-2 treatment-related irAEs: HR = 0.83, 95% CI = 0.67-1.01, p = .067 and grade 3-4: HR = 1.35, 95% CI = 1.02-1.78, p = .037 compared to no treatment-related irAEs. Grade 1-2 dermatologic toxicity was associated with improved OS compared to other grade 1-2 toxicities (HR = 0.67, 95% CI = 0.52-0.85, p = .002). There was no significant OS difference between patients with Grade 1-2 fatigue, gastrointestinal, metabolic, hepatic, endocrine, and thyroid toxicities vs other Grade 1-2 toxicities.
Conclusions: In this large cohort of patients with rare tumors receiving checkpoint inhibitor therapy, grade of irAE in the first cycle was predictive for survival.
|
Journal of the National Cancer Institute
Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance)
Ma C, Meyerhardt JA
BACKGROUND: Inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset by sufficient physical activity remains unknown.
METHODS: This cohort study was nested within the Cancer and Leukemia Group B (now part of the Alliance for Clinical Trials in Oncology) and Southwest Oncology Group randomized trial. Inflammatory burden was quantified by high-sensitivity C-reactive protein, interleukin-6, and soluble tumor necrosis factor-? receptor 2 after recovery from tumor resection. Physical activity was measured during and after postoperative chemotherapy. The primary endpoint was disease-free survival.
RESULTS: The 3-year disease-free survival rate was 88.4% among patients with low inflammation and sufficient physical activity (referent group for all comparisons), 84.9% with low inflammation and insufficient physical activity (absolute risk difference = -3.5 percentage points, 95% confidence interval [CI] = -11.3 to 4.3; P?=?.38), 78.0% with intermediate inflammation and insufficient physical activity (absolute risk difference = -10.4 percentage points, 95% CI = -17.4 to -3.3; P?=?.007), and 79.7% with high inflammation and insufficient physical activity (absolute risk difference = -8.7 percentage points, 95% CI = -15.7 to -1.6; P?=?.022). In contrast, the 3-year disease-free survival rate was 87.3% among patients with intermediate inflammation and sufficient physical activity (absolute risk difference = -1.1 percentage points, 95% CI = -7.5 to 5.3; P?=?.74) and 84.4% with high inflammation and sufficient physical activity (absolute risk difference = -4.0 percentage points, 95% CI = -12.3 to 4.3; P?=?.34).
CONCLUSION: In this observational study of stage III colon cancer patients, physical activity was associated with improved disease-free survival despite high inflammation. Patients with intermediate or high inflammation who were physically active had disease-free survival rates that were not statistically significantly different from those with low inflammation.
|
Nature Chemical Biology
Template-Assisted Covalent Modification Underlies Activity of Covalent Molecular Glues
Li YD, Ma MW, Hunkeler M, Puvar K, Rutter JC, Lumpkin RJ, Sandoval B, Jin CY, Schmoker AM, Ficarro SB, Cheong H, Metivier RJ, Wang MY, Xu S, Groendyke BJ, Sigua LH, Tavares I, Zou C, Tsai JM, Park PMC, Yoon H, Sperling HT, Marto JA, Qi J, Nowak RP, Donovan KA, S?abicki M, Fischer ES, Ebert BL
Molecular glues are proximity-inducing small molecules that have emerged as an attractive therapeutic approach. However, developing molecular glues remains challenging, requiring innovative mechanistic strategies to stabilize neoprotein interfaces and expedite discovery. Here we unveil a trans-labeling covalent molecular glue mechanism, termed 'template-assisted covalent modification'. We identified a new series of BRD4 molecular glue degraders that recruit CUL4DCAF16 ligase to the second bromodomain of BRD4 (BRD4BD2). Through comprehensive biochemical, structural and mutagenesis analyses, we elucidated how pre-existing structural complementarity between DCAF16 and BRD4BD2 serves as a template to optimally orient the degrader for covalent modification of DCAF16Cys58. This process stabilizes the formation of BRD4-degrader-DCAF16 ternary complex and facilitates BRD4 degradation. Supporting generalizability, we found that a subset of degraders also induces GAK-BRD4BD2 interaction through trans-labeling of GAK. Together, our work establishes 'template-assisted covalent modification' as a mechanism for covalent molecular glues, which opens a new path to proximity-driven pharmacology.
|
Nature Medicine
Trastuzumab Deruxtecan in HER2-Positive Advanced Breast Cancer with or without Brain Metastases: A Phase 3b/4 Trial
Lin NU
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previously treated and progressing) brain metastases (BMs). The phase 3b/4 DESTINY-Breast12 study investigated T-DXd in patients with HER2+ mBC and is, to our knowledge, the largest prospective study of T-DXd in patients with BMs in this setting. Patients (stable/active BMs (n?=?263) and no BMs (n?=?241)) treated with one or more prior anti-HER2-based regimens received T-DXd (5.4?mg per kg). Primary endpoints were progression-free survival (PFS; BMs cohort) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (non-BMs cohort). Additional endpoints included central nervous system (CNS) PFS, ORR, time to second progression, CNS ORR (BMs cohort), incidence of new symptomatic CNS metastases (non-BMs cohort), time to progression, duration of response, overall survival and safety (both cohorts). No formal hypothesis testing was conducted for this single-arm, open-label study. In the BMs cohort, 12-month PFS was 61.6% (95% confidence interval (CI): 54.9-67.6), and 12-month CNS PFS was 58.9% (95% CI: 51.9-65.3). In the non-BMs cohort, ORR was 62.7% (95% CI: 56.5-68.8). Grade 3 or higher adverse events occurred in 51% (BMs cohort) and 49% (non-BMs cohort) of patients. Investigator-reported interstitial lung disease/pneumonitis occurred in 16% (grade ?3: 3%) of patients with BMs and 13% (grade ?3: 1%) of patients without BMs. These data show substantial and durable overall and intracranial activity for T-DXd, supporting its use in previously treated patients with HER2+ mBC irrespective of stable/active baseline BMs. ClinicalTrials.gov identifier: NCT04739761.
|
American Journal of Respiratory and Critical Care Medicine
Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene
Rose JA, Tukpah AC, Cutting C, Wada N, Nishino M, Moll M, Kalra S, Choi B, Raby BA, San José Estépar R, Washko GR, Silverman EK, Cho MH, Hatabu H, Putman RK, Hunninghake GM
|
|
|
Blood Advances
Myeloid Clonal Hematopoiesis of Indeterminate Potential in Patients with Chronic Lymphocytic Leukemia
Volpe VO, Sekar A, Santos Azevedo R, Mikhaleva M, Gibson CJ, Martindale SP, Fardoun R, Tyekucheva S, Ren Y, Fernandes SM, Knisbacher BA, Hahn CK, Getz G, Wu CJ, Davids MS, Brown JR
|
Blood Advances
Risk of Bleeding in Patients with Essential Thrombocythemia and Extreme Thrombocytosis
Redd RA, Harris AC, Aryee MJ, Marneth AE, Kamaz B, Kim CJ, Weeks LD, Stahl M, DeAngelo DJ, Lindsley RC, Luskin MR, Hobbs GS, How J
|
|
|
Clinical Cancer Research
Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hanna GJ, Oakley LB, Shi R, ONeill A, Shin KY, Scarfo N, Sehgal K, Dennis MJ, Quinn N, Jo VY, Wong K, Haddad RI
|
JCO Oncology Practice
Experience and Needs of Patients with Young-Onset Colorectal Cancer and Their Caregivers: A Qualitative Study
Fletcher KM, Revette A, Enzinger A, Biller L, Brais L, Arsenault B, McCleary N, Chan J, Boyle K, Meyerhardt JA, Ng K
|
JCO Precision Oncology
Prevalence and Distribution of Unexpected Actionable Germline Pathogenic Variants Identified on Broad-Based Multigene Panel Testing Among Patients with Cancer
Kipnis L, Barquet Ramos F, Breen KM, Patton K, Morrissette A, Buehler RM, Ukaegbu C, Yurgelun MB, Syngal S, Rana HQ, Garber JE
|
Nature Methods
The Dynamics of Hematopoiesis over the Human Lifespan
Li H, Ezike J, Frenis K, Tanaka-Yano M, Tarantino G, Whangbo J, Morris V, Wang D, Chen AF, Bianchi G, Daley GQ, Garg S, Liu D, Rowe RG
|
Neuro-Oncology
A Comparative Analysis of IDH-Mutant Glioma in Pediatric, Young Adult, and Older Adult Patients
Lim-Fat MJ, Touat M, Vogelzang J, Sousa C, Pisano W, Geduldig J, Bhave V, Driver J, Kao PC, McGovern A, Ma C, Wright KD, London WB, Warren KE, Wen PY, Bi WL, Alexandrescu S, Reardon DA, Ligon KL, Yeo KK
|
Structure
Structural Insights into the DNA-Binding Mechanism of BCL11A: The Integral Role of ZnF6
Viennet T, Yin M, Jayaraj A, Kim W, Sun ZJ, Fujiwara Y, Zhang K, Seruggia D, Seo HS, Dhe-Paganon S, Orkin SH, Arthanari H
|
|
|
|
